CN114555607A - 一类靶向蛋白质水解通路的功能分子及其制备和应用 - Google Patents

一类靶向蛋白质水解通路的功能分子及其制备和应用 Download PDF

Info

Publication number
CN114555607A
CN114555607A CN202080070688.4A CN202080070688A CN114555607A CN 114555607 A CN114555607 A CN 114555607A CN 202080070688 A CN202080070688 A CN 202080070688A CN 114555607 A CN114555607 A CN 114555607A
Authority
CN
China
Prior art keywords
compound
preparation
pharmaceutically acceptable
group
hrms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080070688.4A
Other languages
English (en)
Other versions
CN114555607B (zh
Inventor
张崇敬
王福嘉
叶子
杨婉琪
李珂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Materia Medica of CAMS
Original Assignee
Institute of Materia Medica of CAMS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Materia Medica of CAMS filed Critical Institute of Materia Medica of CAMS
Publication of CN114555607A publication Critical patent/CN114555607A/zh
Application granted granted Critical
Publication of CN114555607B publication Critical patent/CN114555607B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明属于医药技术领域，涉及一类靶向蛋白质水解通路的功能小分子及其制备和应用。具体涉及如式(M)所示的功能小分子及其药学上可接受的盐，以及这些化合物和其药用组合物在制备治疗肿瘤药物中的应用。本发明将含有过氧桥键的化合物和E3泛素连接酶复合体的底物连接获得功能化小分子。本发明涉及的功能分子能够混杂靶向结合包括蛋白质水解通路中功能蛋白的多种蛋白质，具有抗肿瘤生物活性。
Figure DDA0003586639510000011

Description

PCT国内申请，说明书已公开。

Claims (11)

  1. PCT国内申请，权利要求书已公开。
CN202080070688.4A 2019-09-09 2020-09-09 一类靶向蛋白质水解通路的功能分子及其制备和应用 Active CN114555607B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910848612.9A CN112457365B (zh) 2019-09-09 2019-09-09 一类靶向蛋白质水解通路的功能分子及其制备和应用
CN2019108486129 2019-09-09
PCT/CN2020/114125 WO2021047524A1 (zh) 2019-09-09 2020-09-09 一类靶向蛋白质水解通路的功能分子及其制备和应用

Publications (2)

Publication Number Publication Date
CN114555607A true CN114555607A (zh) 2022-05-27
CN114555607B CN114555607B (zh) 2023-11-28

Family

ID=74807506

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910848612.9A Active CN112457365B (zh) 2019-09-09 2019-09-09 一类靶向蛋白质水解通路的功能分子及其制备和应用
CN202080070688.4A Active CN114555607B (zh) 2019-09-09 2020-09-09 一类靶向蛋白质水解通路的功能分子及其制备和应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201910848612.9A Active CN112457365B (zh) 2019-09-09 2019-09-09 一类靶向蛋白质水解通路的功能分子及其制备和应用

Country Status (4)

Country Link
US (1) US20220380381A1 (zh)
EP (1) EP4043467A4 (zh)
CN (2) CN112457365B (zh)
WO (1) WO2021047524A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112457365B (zh) * 2019-09-09 2023-06-09 中国医学科学院药物研究所 一类靶向蛋白质水解通路的功能分子及其制备和应用
CN116655651A (zh) * 2023-05-31 2023-08-29 中国医学科学院药物研究所 青蒿素10位碳取代衍生物差向异构体的制备及应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106749513A (zh) * 2017-01-23 2017-05-31 中国药科大学 基于vhl配体诱导bet降解的双功能分子及其制备和应用
WO2018081530A1 (en) * 2016-10-28 2018-05-03 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating ezh2-mediated cancer
WO2018106870A1 (en) * 2016-12-08 2018-06-14 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating cdk4/6-mediated cancer
US20190233433A1 (en) * 2018-01-26 2019-08-01 Yale University Imide-based modulators of proteolysis and associated methods of use
CN110143961A (zh) * 2019-06-27 2019-08-20 江苏省中医药研究院 一种基于vhl配体诱导bet降解的吡咯并吡啶酮类双功能分子化合物
CN112457365A (zh) * 2019-09-09 2021-03-09 中国医学科学院药物研究所 一类靶向蛋白质水解通路的功能分子及其制备和应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201504314D0 (en) * 2015-03-13 2015-04-29 Univ Dundee Small molecules

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018081530A1 (en) * 2016-10-28 2018-05-03 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating ezh2-mediated cancer
WO2018106870A1 (en) * 2016-12-08 2018-06-14 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating cdk4/6-mediated cancer
CN106749513A (zh) * 2017-01-23 2017-05-31 中国药科大学 基于vhl配体诱导bet降解的双功能分子及其制备和应用
US20190233433A1 (en) * 2018-01-26 2019-08-01 Yale University Imide-based modulators of proteolysis and associated methods of use
CN110143961A (zh) * 2019-06-27 2019-08-20 江苏省中医药研究院 一种基于vhl配体诱导bet降解的吡咯并吡啶酮类双功能分子化合物
CN112457365A (zh) * 2019-09-09 2021-03-09 中国医学科学院药物研究所 一类靶向蛋白质水解通路的功能分子及其制备和应用

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHIARA MANIACI等: "Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation", vol. 8, no. 830, pages 1 - 14 *
GADD MS等: "Structural basis of PROTAC cooperative recognition for selective protein degradation", vol. 13, pages 514 - 521, XP055422543, DOI: 10.1038/nchembio.2329 *
STEVE OH等: "Synthesis and anti-cancer activity of covalent conjugates of artemisinin and a transferrin-receptor targeting peptide", vol. 274, no. 1, pages 33 - 39, XP025817758, DOI: 10.1016/j.canlet.2008.08.031 *
XIN SUN等: "Targeting autophagy enhances the anticancer effect of artemisinin and its derivatives", vol. 39, no. 6, pages 2172 - 2193, XP055790533, DOI: 10.1002/med.21580 *
杨婉琪等: "基于分子原型和分子探针的药用活性分子蛋白作用靶标研究", vol. 55, no. 7, pages 1439 - 1452 *

Also Published As

Publication number Publication date
US20220380381A1 (en) 2022-12-01
CN112457365A (zh) 2021-03-09
EP4043467A4 (en) 2023-11-08
CN114555607B (zh) 2023-11-28
CN112457365B (zh) 2023-06-09
WO2021047524A1 (zh) 2021-03-18
EP4043467A1 (en) 2022-08-17

Similar Documents

Publication Publication Date Title
CN114901663A (zh) 一类芳香杂环类化合物及其在药物中的应用
CN114057702B (zh) 一种新型冠状病毒主蛋白酶的抑制剂及其制备方法和用途
KR20140059236A (ko) Hcv 프로테아제 억제제의 결정 형태
KR102558265B1 (ko) 펩타이드 보레이트 에스테르류 화합물의 합성 및 용도
CN112592331B (zh) 一种奥司他韦protac化合物及其制备方法与在抗流感病毒药物中的应用
CN114555607A (zh) 一类靶向蛋白质水解通路的功能分子及其制备和应用
CN112159401A (zh) 偏向性激动剂及其医药用途
KR20240029066A (ko) 케토아미드 유도체 및 이의 용도
CN114380864A (zh) 一种双氢青蒿素衍生物、制备方法、药物组合物和其在制备抗肿瘤药物中的应用
CN107286220B (zh) 1,2,4-三氮唑偶联的二氢杨梅素衍生物及其制备方法和应用
CN112125881B (zh) 4-吡啶取代酞嗪酮类化合物、其制备方法、药物组合物及用途
CN114773356B (zh) 一种倍半萜衍生物、其药物组合物及其制备方法和用途
CN113024557B (zh) 一种Peganumine A生物碱结构简化物及其应用
KR101766822B1 (ko) 디페닐설페이트 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 c형 간염 바이러스 관련 질환의 예방 또는 치료용 약학적 조성물
CA3193057A1 (en) Polymorphs of an ssao inhibitor
CN112961081B (zh) 一种联苯甲酰胺脲类化合物及其制备方法和应用
CN115260199B (zh) 一种苯并咪唑并吡嗪-3-甲酰胺化合物及其制备方法与应用
CN117343064B (zh) 一种具有抗病毒作用的嘧啶衍生物的制备与应用
CN110092799B (zh) 一种环状化合物、其制备方法和应用
CN114805183B (zh) 一类no供体型荜茇酰胺衍生物、制备方法及用途
EP3498712B1 (en) Spirocyclic indolone polyethylene glycol carbonate compound, composition, preparation method and use thereof
EP2163553A1 (en) Arene connected polyamine macroring derivatives, preparation methods and pharmaceutical uses thereof
CN107698598A (zh) 螺环吲哚酮聚乙二醇碳酸酯类化合物和其组合物、制备方法及用途
CN117736201A (zh) 靶向组蛋白去乙酰化酶8蛋白水解嵌合体、制备方法及其应用
CN117500808A (zh) 蒽类化合物、其制备方法和医药用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant